GlassScriptPhysician profile
Nicholas Blackstone
NPI 1265922066
$7,493.75
in general payments reported to CMS, 2019-2025
17 companies · $6,950 in 2025
The $6,950 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.63 · 2022: $82.74 · 2023: $213 · 2024: $236 · 2025: $6,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Travel and Lodging: $2,687 · Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Travel and Lodging | $2,687.31 |
| Food and Beverage | $712.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,612.71 | 2022-2025 | |
| Medical Device Business Services, INC. | $236.16 | 2024 | Monarch |
| Cook Medical LLC | $198.58 | 2023 | Blue Rhino |
| Astrazeneca Pharmaceuticals LP | $80.21 | 2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $67.93 | 2025 | Trelegy Ellipta, Nucala |
| Pulmonx Corporation | $41.51 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Insmed, INC. | $36.37 | 2025 | Brinsupri, Arikayce |
| Electromed, INC. | $36.20 | 2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $34.58 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.83 | 2025 | Glassia |
| Galderma Laboratories, L.P. | $21.30 | 2025 | Nemluvio |
| Grifols USA, LLC | $19.77 | 2025 | Prolastin-C Liquid |
| Amgen INC. | $17.62 | 2025 | Tezspire |
| Verona Pharma, INC. | $17.00 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $15.95 | 2025 | Yupelri |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $14.40 | 2023 | Qutenza |
| Janssen Pharmaceuticals, INC | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Blackstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.